Neupulse, a spinout from the University of Nottingham, has recently secured a £500,000 equity investment through the Midlands Engine Investment Fund II, managed by Mercia Ventures. The company, founded in 2021 by Professors Stephen and Georgina Jackson and Dr Barbara Morera, is developing a non-drug treatment for Tourette’s syndrome. This innovative treatment involves a wristband device that stimulates the median nerve in the wrist and has already shown a 25% reduction in tics during clinical trials. This funding will support Neupulse in the further development, clinical trials, and regulatory approval process of the device. This investment follows a previous £2.5 million investment from a consortium including Eos Advisory and US-based investors.
Ken Cooper, Managing Director, Venture Solutions, at British Business Bank stated, “I’m delighted that the fund is supporting Neupulse…to help bring to market its innovative medical technology.”
The Midlands Engine Investment Fund II, valued at £400 million, provides debt finance from £25,000 to £2 million and equity investment up to £5 million. It is available to businesses located across the Midlands that seek to start up, scale up, or stay ahead.
Sandy Reid, Mercia Ventures, stated that “Neupulse’s device offers a genuine alternative” for the treatment of Tourette’s syndrome, which affects up to 2% of all children worldwide, and this funding will enable the company to bring its device to the market and change people’s lives.
In summary, this recent funding provides Neupulse with the needed capital to complete the development of a breakthrough device for Tourette’s syndrome treatment. Mercia Ventures and the Midlands Engine Investment Fund II will support Neupulse in carrying out additional clinical trials to gain regulatory approval in UK, European, and US markets. With such innovative medical technology, Neupulse will provide new hope for those suffering from Tourette’s, providing a much-needed alternative to current treatments.
